The succesfull treatment of follicular lymphomarelaps performed by 90Y Ibritumomab tiuxetan (Zevalin)
Pacientka úspěšně léčená pro relaps folikulárníholymfomu Ytrium 90 ibritumomab tiuxetanem(Zevalinem)
Radioimunoterapie představuje další krok na cestě k cílené protinádorové léčbě. Ytrium 90 ibritumomabtiuxetanem (Zevalin) byla léčena 57-letá žena pro relaps folikulárního lymfomu. Léčba bylatolerována velmi dobře, provázela ji nekomplikovaná trombocytopenie (3. stupně dle WHO) a neutropenie(2. stupně dle WHO). Metodou PET-CT byla po ukončení léčby potvrzena úplná léčebná odpověď.
Klíčová slova:
radioimunoterapie, Ytrium 90 ibritumomab tiuxetan, folikulární lymfom
Authors:
J. Slabý 1; T. Kozák 1; O. Bělohlávek 2; O. Lang 3
Authors‘ workplace:
Oddělení klinické hematologie, FNKV, Praha, 2PET centrum, Nemocnice Na Homolce, Praha, 3Oddělení nukleární medicíny, FNKV, Praha
1
Published in:
Transfuze Hematol. dnes,, 2004, No. 3, p. 112-113.
Category:
Overview
Radioimmunotherapy represents the other step in specific anti-tumor therapy. 57-years old womanreceived Ytrium 90 ibritumomab tiuxetan (Zevalin) as a treatment of relaps of follicular lymphoma.Treatment was tolerated very well; it was followed by uncomplicated trombocytopenia (Gr. 3, WHOclassification) andneutropenia (Gr. 2,WHOclassification).PET-CT evaluationperformed after finishingof treatment revealed achievement of complete remission.
Key words:
radioimmunotherapy, Ytrium 90 ibritumomab tiuxetan, follicular lymphoma
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2004 Issue 3
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
Most read in this issue
- Myeloid sarcoma (myelosarcoma): classification, diagnosis,biologic manifestation and prognosis
- Dyserythropoiesis and congenital dyserythropoietic anaemias (CDA)
- World apheresis registry and its potential utilization in the CzechRepublic
- Monitoring of hematopoieticrecovery and cytotoxic activity of NK-cells after allogeneichematopoietic cell transplantation.